JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
U.S. Stock Index Futures Steady After S&P 500 Hits Record on Strong Economic Data 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Oil Prices Ease in Asia as Geopolitical Risks Clash With Weak Demand Outlook 
German Exports to the U.S. Decline Sharply as Tariffs Reshape Trade in 2025 
Asian Stock Markets Trade Flat as Holiday Liquidity Thins and BOJ Minutes Watched 
Taiwan Stock Market Ends Higher as Semiconductor and Energy Shares Lead Gains 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Asian Stocks Rise as Wall Street Tech Rally Lifts Markets, Yen Slumps Despite BOJ Rate Hike 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Why U.S. Coffee Prices Are Staying High Despite Trump’s Tariff Rollbacks 
Global Markets Rise as Tech Stocks Lead, Yen Strengthens, and Commodities Hit Record Highs 
Japan Plans $189 Billion Bond Issuance as Record Budget Signals Expansionary Fiscal Policy 
South Korea Central Bank Warns of Rising Financial Stability Risks Amid Won Volatility 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Samsung Biologics Co. was revealed to have won a new CMO contract deal with Pfizer Ireland Pharmaceuticals. The order is said to be worth $183 million, which is equivalent to 15.4% of Samsung Biologic's total sales profits in 2021.
Samsung Biologics is currently the no. 1 contract drug maker in the world based on production capacity. It has bagged this huge contract manufacturing organization (CMO) order from the Ireland unit of Pfizer Inc. the deal just raised expectations that the biotech division of Samsung Group's orders for this year will reach a new record high.
As per The Korea Economic Daily, Samsung Biologics announced its new CMO order through a regulatory filing on Thursday, March 2. Although this was only revealed now, the actual order was made by Pfizer Ireland Pharmaceuticals Ringaskiddy on Feb. 28.
Then again, the biotech firm did not mention the name of the medicine that it will make for Pfizer. It was stated in the contract that the manufacturing will run from Feb. 20, 2023, to Dec. 31, 2029.
In any case, this is the first time that Samsung Biologics or any Korean company has signed a CMO deal with the New York-headquartered pharmaceutical and biotech firm. Korea Joongang Daily reported with the latest business announcement, Samsung Biologics now boasts of having seven of the world's top 10 largest pharmaceutical firms as clients.
The Korean biotech company was established in 2011, and it has started partial operation of its fourth factory in Songdo, Incheon, just recently. This facility will have the capacity to produce 240,000 liters when it goes into full operation in June. This is said to be the largest single pharma production facility in the world.
Meanwhile, Samsung Biologics is investing another KRW 7.5 trillion or about $5.7 billion to build four new plants inside a manufacturing complex near its existing plants in the Songdo region.
